2026-2034年全球口服糖尿病治疗药物市场规模、份额、趋势和成长分析报告

预计口服糖尿病药物的市场规模将从 2025 年的 469.7 亿美元成长到 2034 年的 685.5 亿美元，2026 年至 2034 年的复合年增长率为 4.29%。

受人口老化、都市化和生活型态改变等因素推动，全球第二型糖尿病盛行率不断上升，口服降血糖药市场显着扩张。二甲双胍、磺酰尿素、DPP-4抑制剂、SGLT2抑制剂以及新型固定剂量组合药物製剂等关键治疗药物类别不断丰富治疗选择。诊断率的提高、推荐联合治疗的指南修订以及慢性病门诊管理模式的转变，都促进了市场成长。儘管现有分子药物的非专利渗透率较高，导致销量仍保持高位，但新品牌药已占据了较高的市场份额。

推动成长的因素包括糖尿病盛行率的上升、筛检和诊断范围的扩大，以及临床医生对能够改善心血管和肾臟预后的药物的偏好。保险覆盖范围的扩大和价格合理的学名药的普及，提高了许多地区患者的用药可及性。製药公司的研发重点是具有多重疗效（例如减肥、心臟保护作用）的药物和固定剂量组合药物透过提高用药依从性和简化治疗方法，儘管在某些市场面临价格压力，但仍提升了市场价值。

展望未来，预计将出现向个人化医疗的转变，这种转变将纳入合併症情况和成本效益考量。整合生物感测器和数位技术的护理模式有望透过将口服药物与监测相结合来改善治疗效果。随着专利到期，学名药的竞争将加剧，但新型小分子化合物和联合治疗将开闢新的市场领域。市场成长将取决于能否在可负担性、长期治疗效果数据以及医疗系统容纳不断增长的患者数量的能力之间取得平衡。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球口服糖尿病治疗药物市场：依药物类别划分

• 市场分析、洞察与预测
• 双胍类药物
• Dipeptidyl Peptidase-4 (DPP-4) 抑制剂
• 钠-葡萄糖共同输送体2 (SGLT-2) 抑制剂
• 磺酰尿素类药物
• 胰岛素增敏剂药物
• Meglitinides类药物
• α-Glucosidase酶抑制剂
• 其他药物类别

第五章 全球口服糖尿病治疗药物市场：依疾病类型划分

• 市场分析、洞察与预测
• 2型糖尿病
• 1型糖尿病

第六章 全球口服糖尿病治疗市场：依药物类型划分

• 市场分析、洞察与预测
• 品牌商品
• 非专利的

第七章 全球口服糖尿病治疗药物市场：依通路划分

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 网路药房

第八章 全球口服糖尿病治疗药物市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Eli Lilly And Company
  • Glenmark Pharmaceuticals
  • Johnson & Johnson（Janssen Pharmaceuticals）
  • Merck
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Takeda Pharmaceuticals

The Oral Anti-Diabetic Drug Market size is expected to reach USD 68.55 Billion in 2034 from USD 46.97 Billion (2025) growing at a CAGR of 4.29% during 2026-2034.

The oral anti-diabetic drug market expanded substantially with the rising global prevalence of type 2 diabetes, driven by ageing populations, urbanization, and lifestyle changes. Key therapeutic classes-metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and newer fixed-dose combinations-have broadened treatment options. Market growth was supported by improved diagnosis rates, guideline updates favoring combination therapy, and the shift to chronic outpatient management. Generic penetration for older molecules kept unit volumes high while branded novel agents captured premium shares.

Drivers of growth include increasing diabetes prevalence, greater screening and diagnosis, and clinician preference for drugs with cardiovascular and renal outcome benefits. Payer coverage expansions and the availability of affordable generics have widened patient access in many regions. Pharmaceutical R&D focusing on agents with multifactorial benefits (weight loss, cardioprotection) along with fixed-dose combination pills has encouraged adherence and simplified regimens, lifting market value despite pricing pressures in some markets.

Looking forward, the market will likely evolve toward personalized therapy incorporating comorbidity profiles and cost-effectiveness. Biosensor- and digital-integrated care models may pair oral therapies with monitoring to improve outcomes. Patent expirations of some branded agents will increase generic competition, while novel small molecules and combination therapies could capture new segments. Market growth will hinge on balancing affordability, long-term outcome data, and healthcare system capacity to manage expanding patient numbers.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Biguanides
• Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors
• Sodium-Glucose Transport Protein-2 (Sglt-2) Inhibitors
• Sulfonylureas
• Thiazolidinediones
• Meglitinides
• Alpha-Glucosidase Inhibitors
• Other Drug Classes

By Disease Type

• Type 2 Diabetes
• Type 1 Diabetes

By Medication Type

• Branded
• Generic

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Glenmark Pharmaceuticals, Johnson Johnson Janssen Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Biguanides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Sodium-Glucose Transport Protein-2 (Sglt-2) Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Sulfonylureas Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Thiazolidinediones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Meglitinides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Alpha-Glucosidase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Type 2 Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Type 1 Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY MEDICATION TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Medication Type
• 6.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Disease Type
  • 8.2.3 By Medication Type
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Disease Type
  • 8.3.3 By Medication Type
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Disease Type
  • 8.4.3 By Medication Type
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Disease Type
  • 8.5.3 By Medication Type
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Disease Type
  • 8.6.3 By Medication Type
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ORAL ANTI-DIABETIC DRUG INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Astellas Pharma
  • 10.2.2 AstraZeneca
  • 10.2.3 Bayer
  • 10.2.4 Boehringer Ingelheim
  • 10.2.5 Bristol Myers Squibb
  • 10.2.6 Eli Lilly And Company
  • 10.2.7 Glenmark Pharmaceuticals
  • 10.2.8 Johnson & Johnson (Janssen Pharmaceuticals)
  • 10.2.9 Merck
  • 10.2.10 Novartis
  • 10.2.11 Novo Nordisk
  • 10.2.12 Pfizer
  • 10.2.13 Sanofi
  • 10.2.14 Takeda Pharmaceuticals